You are here: Home > Projects and Research lines > A phase III randomized, placebo controlled, double-blind trial of Sorafenib + Erlotinib vs. Sorafenib + placebo as First Line systemic treatment for HCC (SEARCH)
Projects and Research lines
A phase III randomized, placebo controlled, double-blind trial of Sorafenib + Erlotinib vs. Sorafenib + placebo as First Line systemic treatment for HCC (SEARCH)

Bayer Pharmaceuticals

Clinical research: Clinical trials in liver cancer

Liver Cancer Translational Research Laboratory

BCLC-IDIBAPS, Liver Unit, Hospital Clínic · Esther Koplowitz Center, 3rd Floor
Rosselló 153 · 08036 Barcelona · Tel: +34 93 227 9155

© Liver Cancer Translational Research Laboratory - IDIBAPS 2011 - 2017